Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Top Cited Papers
- 1 September 2017
- journal article
- Published by Elsevier in The Lancet
- Vol. 390 (10101) , 1511-1520
- https://doi.org/10.1016/s0140-6736(17)31665-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical TrialPLOS ONE, 2013
- Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionNature Biotechnology, 2012
- CD4+T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infectionEuropean Journal of Immunology, 2012
- Devices for intradermal vaccinationVaccine, 2012
- Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injectorVaccine, 2011
- SPICE: Exploration and analysis of post‐cytometric complex multivariate datasetsCytometry Part A, 2011
- Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma PatientsJournal of Immunotherapy, 2009
- Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever VaccinesImmunity, 2008
- Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNAJournal of Immunotherapy, 2008
- Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccinesCellular and Molecular Life Sciences, 2004